Procter & Gamble Health Ltd. (IN:PGHL)
:PGHL
Want to see IN:PGHL full AI Analyst Report?
Top Page
Procter & Gamble Health Ltd.
(PGHL)
Select Model
Select Model
Rating:73Outperform
Price Target:
₹5,743.00
▼(-0.15% Downside)
Action:Reiterated
Date:10/21/25
Procter & Gamble Health Ltd. demonstrates strong financial performance with robust profitability and a solid balance sheet, contributing significantly to the overall score. The technical analysis indicates mixed signals with short-term bearish momentum but a long-term bullish trend. The valuation is slightly high, reflecting growth expectations, but the attractive dividend yield provides a buffer. The absence of earnings call data and corporate events does not impact the score.
Positive Factors
Balance Sheet Strength
Extremely low leverage and very high ROE provide durable financial flexibility. This capital structure supports sustained investment in distribution, marketing, and working capital, reduces default risk in downturns, and enables consistent shareholder returns or opportunistic M&A over months to years.
Negative Factors
Margin Pressure
A falling gross margin signals input cost or mix pressure that can erode durable profitability if persistent. Without offsetting pricing or productivity gains, margin compression reduces cash available for reinvestment and weakens long-term earnings resilience.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance Sheet Strength
Extremely low leverage and very high ROE provide durable financial flexibility. This capital structure supports sustained investment in distribution, marketing, and working capital, reduces default risk in downturns, and enables consistent shareholder returns or opportunistic M&A over months to years.
Read all positive factors
Procter & Gamble Health Ltd. (PGHL) vs. iShares MSCI India ETF (INDA)
Market Cap
₹88.67B
Dividend Yield3.28%
Average Volume (3M)310.00
Price to Earnings (P/E)30.5
Beta (1Y)0.54
Revenue Growth9.13%
EPS Growth4.38%
CountryIN
Employees1,336
SectorConsumer Defensive
Sector Strength42
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)184.83
Shares Outstanding16,599,382
10 Day Avg. Volume340
30 Day Avg. Volume310
Financial Highlights & Ratios
PEG Ratio1.37
Price to Book (P/B)15.96
Price to Sales (P/S)7.03
P/FCF Ratio51.22
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)219
Revenue Forecast (FY)N/A
Procter & Gamble Health Ltd. Business Overview & Revenue Model
Company Description
Procter & Gamble Health Limited manufactures and markets pharmaceuticals and chemicals in India. It provides over-the-counter products, vitamins, minerals, and supplements. The company offers its products under the Polybion, Neurobion, Evion, Nasi...
How the Company Makes Money
PGHL primarily makes money by manufacturing (and/or sourcing) consumer healthcare products and selling them in India through trade channels such as pharmacies, chemists, modern retail, and distributors, generating revenue from the sale of finished...
Procter & Gamble Health Ltd. Financial Statement Overview
Summary
Income Statement
85
Very Positive
Balance Sheet
90
Very Positive
Cash Flow
80
Positive
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 12.84B | 12.18B | 11.51B | 12.30B | 11.14B | 10.09B |
| Gross Profit | 8.88B | 8.69B | 8.09B | 8.46B | 7.61B | 6.84B |
| EBITDA | 4.20B | 3.62B | 3.03B | 3.19B | 2.65B | 2.42B |
| Net Income | 3.07B | 2.51B | 2.01B | 2.29B | 1.93B | 1.77B |
Balance Sheet | ||||||
| Total Assets | 8.94B | 7.94B | 7.94B | 11.01B | 8.94B | 9.86B |
| Cash, Cash Equivalents and Short-Term Investments | 2.86B | 1.89B | 2.44B | 4.53B | 3.19B | 4.64B |
| Total Debt | 95.50M | 76.20M | 95.60M | 120.00M | 28.30M | 76.10M |
| Total Liabilities | 2.75B | 2.57B | 2.56B | 3.50B | 2.77B | 2.82B |
| Stockholders Equity | 6.20B | 5.37B | 5.38B | 7.51B | 6.16B | 7.04B |
Cash Flow | ||||||
| Free Cash Flow | 2.12B | 1.67B | 2.07B | 1.94B | 1.32B | 1.95B |
| Operating Cash Flow | 2.21B | 1.76B | 2.28B | 2.36B | 1.70B | 2.47B |
| Investing Cash Flow | 13.60M | 24.40M | -68.70M | -215.00M | -255.40M | -322.70M |
| Financing Cash Flow | -2.10B | -2.35B | -4.18B | -984.70M | -2.89B | -3.87B |
Procter & Gamble Health Ltd. Technical Analysis
Positive
5751.70
Price Trends
5013.92
Positive
5200.79
Positive
5647.79
Negative
Market Momentum
74.98
Negative
61.43
Neutral
68.68
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:PGHL, the sentiment is Positive. The current price of 5751.7 is above the 20-day moving average (MA) of 5211.91, above the 50-day MA of 5013.92, and above the 200-day MA of 5647.79, indicating a neutral trend. The MACD of 74.98 indicates Negative momentum. The RSI at 61.43 is Neutral, neither overbought nor oversold. The STOCH value of 68.68 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:PGHL.
Procter & Gamble Health Ltd. Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | ₹881.60B | 18.87 | ― | 0.33% | 7.31% | 0.34% | |
73 Outperform | ₹88.67B | 30.50 | ― | 3.28% | 9.13% | 4.38% | |
68 Neutral | ₹1.07T | 55.46 | ― | 0.04% | 16.27% | -6.07% | |
64 Neutral | ₹1.05T | 22.07 | ― | 1.19% | 16.81% | 11.38% | |
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
59 Neutral | ₹16.16B | 24.65 | ― | 0.68% | 11.23% | 13.89% | |
53 Neutral | ₹670.97B | 35.61 | ― | 0.24% | 25.44% | ― |
* Consumer Defensive Sector Average
IN:PGHL
Procter & Gamble Health Ltd.
5,341.65
4.91
0.09%
IN:AMRUTANJAN
Amrutanjan Health Care Limited
552.75
-155.54
-21.96%
IN:AUROPHARMA
Aurobindo Pharma Ltd
1,517.90
318.45
26.55%
IN:GLENMARK
Glenmark Pharmaceuticals Limited
2,377.65
941.43
65.55%
IN:MANKIND
Mankind Pharma Ltd.
2,583.35
51.30
2.03%
IN:ZYDUSLIFE
Zydus Lifesciences Limited
1,040.95
161.28
18.33%
Procter & Gamble Health Ltd. Corporate Events
Procter & Gamble Health Books ₹32 Crore Gain From Mumbai Property Sale
Apr 30, 2026
Procter Gamble Health Ltd. has executed a sale deed for certain immovable properties located in Mumbai, in line with disclosure requirements under Indian securities regulations. The transaction will generate an estimated profit of about INR 32 cr...
Procter & Gamble Health Posts Strong Q3 FY26 Results, Announces ₹160 Interim Dividend with Special Payout
Feb 6, 2026
Procter Gamble Health Limited reported unaudited financial results for the quarter ended 31 December 2025, with revenue from operations rising to ₹37,386 lakh and net profit for the quarter at ₹7,759 lakh, contributing to a nine‑...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.